Inside informationEnglish
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Transgene S.A.
- Filed
- 22/05/2025, 17:45
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 118381_20250522